Shots:

• Iktos to receive research funding & is eligible to receive additional fees upon achievement of milestones. ONO will obtain exclusive rights globally to develop & commercialize small molecule compounds
• The collaboration will use Iktos' de novo ligand & structure-based generative modeling technologies & software Makya (AI-based retrosynthesis analysis) along with planning tool Spaya to enable the exploration of chemical space & produces innovative molecule designs with optimized properties
• The collaboration will complement Ono’s drug discovery capabilities to identify pre-clinical candidates & an additional novel chemical matter with suitable properties for undisclosed drug discovery programs

Ref: Businesswire | Image: Iktos